Bruce Cozadd Sells 18,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 18,000 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $181.09, for a total transaction of $3,259,620.00. Following the sale, the director owned 390,826 shares in the company, valued at $70,774,680.34. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jazz Pharmaceuticals Trading Down 0.2%

JAZZ traded down $0.34 on Thursday, reaching $175.74. 1,664,525 shares of the company traded hands, compared to its average volume of 947,213. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The company has a market cap of $10.68 billion, a P/E ratio of -26.11, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. The firm has a fifty day simple moving average of $137.84 and a two-hundred day simple moving average of $121.95. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the firm posted $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in JAZZ. Hurley Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $25,000. Picton Mahoney Asset Management boosted its stake in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 269 shares during the period. Farther Finance Advisors LLC increased its stake in Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 234 shares during the period. SVB Wealth LLC acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth about $36,000. Finally, Hantz Financial Services Inc. raised its holdings in Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 297 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Morgan Stanley boosted their target price on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a report on Monday. JPMorgan Chase & Co. lowered their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, The Goldman Sachs Group increased their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $195.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.